Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | ARID1A Q456* |
Gene Variant Detail | |
Relevant Treatment Approaches | EZH2 inhibitor |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
ARID1A Q456* | colorectal cancer | sensitive | Olaparib | Preclinical | Actionable | In a preclinical study, Lynparza (olaparib) inhibited proliferation and colony formation of a colorectal cancer cell line harboring ARID1A Q456* in culture (PMID: 26069190). | 26069190 | |
ARID1A Q456* | colorectal cancer | sensitive | Talazoparib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Talzenna (talazoparib) inhibited colony formation and proliferation of a human colorectal cancer cell line harboring ARID1A Q456* in culture and inhibited tumor formation in colorectal cancer xenografts harboring ARID1A Q456* (PMID: 26069190). | 26069190 | |
ARID1A Q456* | colorectal cancer | sensitive | Rucaparib | Preclinical - Cell culture | Actionable | In a preclinical study, Rubraca (rucaparib) treatment resulted in increased apoptosis of colorectal cancer cells harboring ARID1A Q456* in culture (PMID: 26069190). | 26069190 | |
ARID1A Q456* | colorectal cancer | sensitive | Dasatinib | Preclinical - Cell culture | Actionable | In a preclinical study, a colorectal cancer cell line homozygously expressing ARID1A Q456* demonstrated sensitivity to treatment with Sprycel (dasatinib) in culture (PMID: 27364904). | 27364904 | |
ARID1A Q456* | colorectal cancer | sensitive | VE-821 | Preclinical - Cell culture | Actionable | In a preclinical study, colorectal cancer cells homozygous for ARID1A Q456* were sensitive to VE-821 in in vitro assays, demonstrating decrease cell survival (PMID: 27958275). | 27958275 | |
ARID1A Q456* | colorectal cancer | sensitive | Berzosertib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Berzosertib (VX-970) treatment in colorectal cancer cells homozygous for ARID1A Q456* resulted in decreased cell survival in culture, and tumor growth inhibition in cell line xenograft models (PMID: 27958275). | 27958275 |